NCT00527397 - Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1

Interventions

DRUG

CP-464,005

Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.

DRUG

CP-464,005

Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.

DRUG

CP-464,005

Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.

Trial Locations (10)

Unknown

Pfizer Investigational Site, Nagoya

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Tenri-shi

Pfizer Investigational Site, Takatsuki-shi

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Bunkyo-ku

Pfizer Investigational Site, Meguro-ku

Pfizer Investigational Site, Toyama

Pfizer Investigational Site, Tokyo